 |
Journal articles
Late presentation for HCV care: Time to target people with diabetes and/or hazardous alcohol use (ANRS CO22 HEPATHER cohort)
Melina Santos
1, 2
Camelia Protopopescu
1, 2
Elizabeth Delarocque‐astagneau
3, 4
Marc Bourlière
5
Ventizlava Petrov‐sanchez
6
Vincent Di Beo
1, 2
Dominique Larrey
7, 8
Maël Baudoin
1, 2
Céline Dorival
9
Morgane Bureau
1, 2
Hélène Fontaine
10, 11
Fabrice Carrat
9, 12
Fabienne Marcellin
1, 2
Stanislas Pol
10, 11
Patrizia Carrieri
1, 2
Melina Santos 1, 2
Author
Camelia Protopopescu 1, 2
Author ORCID : https://orcid.org/0000-0003-0164-7917
Elizabeth Delarocque‐astagneau 3, 4
Author
Marc Bourlière 5
Author
Ventizlava Petrov‐sanchez 6
Author ORCID : https://orcid.org/0000-0002-8171-5416
Vincent Di Beo 1, 2
Author
Dominique Larrey 7, 8
Author
Maël Baudoin 1, 2
Author
Céline Dorival 9
Author
Morgane Bureau 1, 2
Author
Hélène Fontaine 10, 11
Author ORCID : https://orcid.org/0000-0003-4853-1786
Fabrice Carrat 9, 12
Author ORCID : https://orcid.org/0000-0002-8672-7918
Fabienne Marcellin 1, 2
Author IdHAL : fabienne-marcellin ORCID : https://orcid.org/0000-0001-8853-3829
Stanislas Pol 10, 11
Author ORCID : https://orcid.org/0000-0001-9772-9591
Patrizia Carrieri 1, 2
Author ORCID : https://orcid.org/0000-0002-6794-4837
1
SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD - Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (Faculté de Médecine - Site Timone - 27 Bd Jean Moulin 13385 Marseille Cedex 05. - France)
- IRD - Institut de Recherche pour le Développement : UMR 259 (Siège Le Sextant 44, bd de Dunkerque CS 90009 13572 Marseille cedex 02 - France)
- AMU - Aix Marseille Université (Aix-Marseille Université Jardins du Pharo 58 Boulevard Charles Livon 13284 Marseille cedex 7 - France)
- INSERM - Institut National de la Santé et de la Recherche Médicale : U1252 (101, rue de Tolbiac, 75013 Paris - France)
3
CESP - Centre de recherche en épidémiologie et santé des populations (16 avenue Paul Vaillant Couturier 94807 Villejuif Cedex, France - France)
- UVSQ - Université de Versailles Saint-Quentin-en-Yvelines : UMR U1018 (55 avenue de Paris - 78035 Versailles cedex - France)
- AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) (France)
- Hôpital Paul Brousse (12 Avenue Paul Vaillant Couturier, 94800 Villejuif - France)
- INSERM - Institut National de la Santé et de la Recherche Médicale : U1018 (101, rue de Tolbiac, 75013 Paris - France)
- Université Paris-Saclay (Bâtiment Bréguet, 3 Rue Joliot Curie 2e ét, 91190 Gif-sur-Yvette - France)
4
Hôpital Raymond Poincaré [AP-HP] (104 Boulevard Raymond Poincaré, 92380 Garches - France)
5
Hôpital Saint-Joseph [Marseille] (Hôpital Saint-Joseph
26 Boulevard de Louvain, 13000 Marseille - France)
7
Hôpital Saint-Éloi [Montpellier] (France)
- CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier] (191 avenue du doyen Gaston Giraud 34295 Montpellier cedex 5 - France)
8
Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB) (Institute for Regenerative Medicine and Biotherapy - 80 rue Augustin Fliche 34295 Montpellier - Cedex 5 - France)
- UM - Université de Montpellier (163 rue Auguste Broussonnet - 34090 Montpellier - France)
- INSERM - Institut National de la Santé et de la Recherche Médicale : U1183 (101, rue de Tolbiac, 75013 Paris - France)
- CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier] (191 avenue du doyen Gaston Giraud 34295 Montpellier cedex 5 - France)
9
iPLESP - Institut Pierre Louis d'Epidémiologie et de Santé Publique (56, boulevard Vincent Auriol - CS 81393 - 75646 Paris Cedex 13 - France)
- INSERM - Institut National de la Santé et de la Recherche Médicale : U1136 (101, rue de Tolbiac, 75013 Paris - France)
- SU - Sorbonne Université (21 rue de l’École de médecine - 75006 Paris - France)
10
Hôpital Cochin [AP-HP] (27 Rue du Faubourg Saint-Jacques 75014 Paris - France)
11
Inserm U1223 - Physiopathologie du système immunitaire (Institut Pasteur 25-28, rue du Docteur Roux 75724 Paris cedex 15 - France)
- INSERM - Institut National de la Santé et de la Recherche Médicale : U1223 (101, rue de Tolbiac, 75013 Paris - France)
- Institut Pasteur [Paris] (25-28, rue du docteur Roux, 75724 Paris cedex 15 - France)
12
CHU Saint-Antoine [AP-HP] (184, rue du Faubourg Saint-Antoine
75571 Paris cedex 12 - France)
- AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) (France)
- SU - Sorbonne Université (21 rue de l’École de médecine - 75006 Paris - France)
Abstract : Background and aims: Late presentation for care of hepatitis C virus (HCV) infection - defined as having severe liver fibrosis when first consulting a specialist for HCV care - increases morbidity and mortality. Identifying the socio-behavioural correlates of late presentation is essential to improve HCV strategies to optimize HCV cascade of care. We investigated clinical and socio-behavioural correlates of late presentation for care in HCV mono-infected individuals.
Methods: This study included chronic HCV mono-infected patients participating in the French national cohort ANRS CO22 HEPATHER, starting in 2012. The correlates of late presentation were estimated using a Heckman probit selection model, which takes into account the possible selection bias because of missing data in the outcome.
Results: Among the 9174 study patients, 1236 had available data on liver fibrosis stage at first presentation for HCV care. Of these, 591 (47.8%) were late presenters. In a multivariable analysis adjusted for age, sex and HCV genotype, having diabetes (adjusted coefficient [95% confidence interval]: 0.55 [0.30; 0.80]), current hazardous alcohol use (0.36 [0.03; 0.69]) and current abstinence but past hazardous alcohol use (0.42 [0.19; 0.64]) (vs. current abstinence and no past hazardous use) were all independently associated with late presentation for HCV care.
Conclusions: As late presentation severely affects HCV cascade of care, our findings bring important new evidence about the need to promptly identify and target people with diabetes and/or past or current hazardous alcohol use for HCV screening and treatment within the wider context of the WHO goal to eliminate HCV by 2030.
Document type :
Journal articles
Domain :
Complete list of metadata
https://www.hal.inserm.fr/inserm-03465070
Contributor : Odile Malbec Connect in order to contact the contributor
Submitted on : Friday, December 3, 2021 - 4:00:22 PM
Last modification on : Wednesday, January 26, 2022 - 4:45:43 PM
Contributor : Odile Malbec Connect in order to contact the contributor
Submitted on : Friday, December 3, 2021 - 4:00:22 PM
Last modification on : Wednesday, January 26, 2022 - 4:45:43 PM
File
Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamaisPlease log in to resquest access to the document
Identifiers
- HAL Id : inserm-03465070, version 1
- DOI : 10.1111/liv.15056
- PUBMED : 34520614
Collections
INSERM | BS | IPLESP | UNIV-MONTPELLIER | UNIV-AMU | U1252 | SORBONNE-UNIVERSITE | SU-MEDECINE | IRD | UVSQ | SU-TI
Citation
Melina Santos, Camelia Protopopescu, Elizabeth Delarocque‐astagneau, Marc Bourlière, Ventizlava Petrov‐sanchez, et al.. Late presentation for HCV care: Time to target people with diabetes and/or hazardous alcohol use (ANRS CO22 HEPATHER cohort). Liver International, Wiley-Blackwell, 2021, Online ahead of print. ⟨10.1111/liv.15056⟩. ⟨inserm-03465070⟩
Metrics
Les métriques sont temporairement indisponibles